Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Lorus Therapeutics Inc. (OTC BB:LORFF.OB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile
Location
7100 Woodbine Ave., Ontario L3R 5J2
Markham, Canada
Phone: (905) 305-1100
Fax: (905) 305-1584
Email: info@lorusthera.com
Employees (last reported count): 21
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 18%
·Institutional: 1% (1% of float)
(3 institutions)
·Net Inst. Selling: 881.0K shares (+309.77%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Lorus Therapeutic Inc. is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active in-licensing and acquisition program, Lorus is building a portfolio of promising anti-cancer drugs. Included in the Company's portfolio are its two leading antisense therapy candidates, GTI-2040 and GTI-2501, and VIRULIZIN, a potential new drug functioning as a biologic response modifier for the treatment of cancer. The Company also has a license from Ion Pharmaceuticals, Inc. for clotrimazole (CLT), a molecule with anti-angiogenic and anti-proliferative properties, and CLT-related analogues, for anti-cancer indications as well as Kaposi's Sarcoma and actinic keratosis.
More from Market Guide: Expanded Business Description

Financial Summary
Lorus Therapeutics Inc. is a biopharmaceutical company engaged in the research and development of cancer therapies. LORFF is developing new drug candidates that can be used to successfully manage cancer. For the nine months ended 2/28/01, the Company reported no revenues. Net loss totaled C$9.1 million, up from C$3.4 million. Higher loss reflects increased R&D expenses due to the amortization of acquired R&D assets and higher general and administrative expenses.
More from Market Guide: Significant Developments

Officers
FY1999 Pay

Peter Campbell
Interim Chairman
--  
Jim Wright, Ph.D.
Pres and CSO
--  
Guy Ely, M.D.
VP, Drug Devel.
$233K
Aiping Young, M.D., Ph.D.
VP, Research
--  
James Parsons
VP of Fin. and Admin., CFO
--  
Dollar amounts are as of 31-May-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- OTC BB:LORFF.OBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Dec-2000
$0.625
Recent Price$0.72 
52-Week High
on 5-Sep-2000
$2.313
Beta0.86 
Daily Volume (3-month avg)29.0K
Daily Volume (10-day avg)33.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-66.1%
52-Week Change
relative to S&P500
-54.5%
Share-Related Items
Market Capitalization$102.0M
Shares Outstanding141.6M
Float116.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.28 
Earnings (ttm)-$0.07 
Earnings (mrq)-$0.01 
SalesN/A 
Cash (mrq)$0.23 
Valuation Ratios
Price/Book (mrq)2.57 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$7.61M
Income available to common (ttm)-$9.19M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsMay 31
Most recent quarter28-Feb-2001
Management Effectiveness
Return on Assets (ttm)-23.69%
Return on Equity (ttm)-24.70%
Financial Strength
Current Ratio (mrq)22.61 
Debt/Equity (mrq)0 
Total Cash (mrq)$32.5M
Short Interest
As of 8-Oct-1998
Shares Short0 
Shares Short
(Prior Month)
3,000 
Daily Volume3,000 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 28-Feb-2001);   dollar amounts based on an exchange rate of 1.55 Canadian Dollars/US Dollar

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.